Immunovant, Inc.
About Immunovant, Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$505.6M
- Total assets
- $957.0M
- Market cap
- $6.4B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $532.9M
- Income tax
- $215.0K
- Net income
- -$505.6M
- EPS (basic)
- $-2.77
- EPS (diluted)
- $-2.77
Balance sheet
- Total assets
- $957.0M
- Current assets
- $948.8M
- Total liabilities
- $104.4M
- Current liabilities
- $104.4M
- Shareholders’ equity
- $852.6M
Cash flow
- Operating cash flow
- -$407.3M
- Investing cash flow
- -$8.0K
- Financing cash flow
- $595.8M
- Net cash flow
- $188.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.4B
- EPS (diluted)
- $-2.77
- Shares outstanding
- 207.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 21, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $505.6M.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immunovant, Inc..
Write a review
News about Immunovant, Inc.
News & sentiment via Polygon.io
